Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
News Oct 08, 2008
Calando Pharmaceuticals, Inc. has the issuance of U.S. Patent No. 7,427,605, entitled, “Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.”
The patent contains claims directed to inhibitory nucleic acid sequences targeting the Ribonucleotide Reductase Subunit 2 (R2) gene, as well as pharmaceutical compositions and methods for inhibiting tumor growth utilizing the sequences.
R2 is the gene targeted by Calando’s lead siRNA-containing nanoparticle therapeutic, CALAA-01, which is currently in a Phase I clinical trial for patients with non-resectable or metastatic solid tumors. CALAA-01 is the only RNAi therapeutic for cancer to have reached the clinic.
“The issuance of this patent is an important milestone for Calando,” said Dr. Jeremy Heidel, Ph.D., Calando’s Chief Scientific Officer for Nucleic Acid Delivery. “It provides a significant addition to the strong patent portfolio that Calando maintains for its CALAA-01 product.”
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE